In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Hopes To Save FluMist In US With Foreign Data

This article was originally published in The Pink Sheet Daily

Executive Summary

After a CDC advisory committee recommends against the nasal flu vaccine's use in any setting, sponsor AstraZeneca looks to reconcile its effectiveness results with government findings.

You may also be interested in...



FluMist Rejuvenated With CDC Advisory Panel Endorsement; Effectiveness Data Still To Come

US panel votes 12 to 2 to recommend use of nasal vaccine, which has been reformulated to include a new influenza A strain.

FluMist May Not Get CDC Seal Of Approval For Several Years

CDC advisory committee wants vaccine effectiveness data for H1N1 component but that is not the predominant strain this season; AstraZeneca is not giving up.

FDA Supports FluMist Use, Releases Lots For 2016 Flu Season

Despite a CDC advisory committee recommendation that FluMist not be used in the forthcoming influenza season, FDA says the benefits of the nasal formulation outweigh any potential risks.

Topics

Related Companies

UsernamePublicRestriction

Register

PS079542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel